MOTS-c · Research brief

Verify MOTS-C Purity — Lab Testing & Quality Standards

Real Peptides Research TeamEditorial

Updated July 6, 20269 min read

55 WORDS

Short answer

A 2023 analysis published in the Journal of Pharmaceutical Sciences found that nearly 40% of research-grade peptides tested from online suppliers showed purity discrepancies of 5% or more compared to stated specifications. And MOTS-C , a mitochondrial-derived peptide with a precise 16-amino-acid sequence, is particularly vulnerable to degradation during synthesis and storage. Even minor impurities.

Key takeaways

MOTS-C purity below 95% introduces deletion sequences and synthesis byproducts that confound research results by competing for receptor binding without activating AMPK pathways.
Third-party COAs must list the testing lab name, ISO 17025 accreditation, batch number matching your vial, and exact HPLC purity percentage. Generic COAs reused across shipments provide zero verification of your specific product.
Mass spectrometry confirms molecular weight (1,682.01 Da) but does not measure purity; HPLC measures purity but does not confirm sequence identity; amino acid analysis verifies sequence but does not detect non-peptide contaminants.
Lyophilised MOTS-C stored at −20°C retains >95% purity for 24 months; once reconstituted, stability drops to 2–4 weeks at 2–8°C in sterile water or PBS at pH 7.4.
Freeze-thaw cycles degrade peptide structure through ice crystal shearing and methionine oxidation. Aliquot reconstituted solutions into single-use volumes and freeze once, never repeatedly.
Peptide content by weight accounts for residual salts and moisture in lyophilised powder. A vial with 85% peptide content labeled '5mg' contains only 4.25mg active MOTS-C.

A 2023 analysis published in the Journal of Pharmaceutical Sciences found that nearly 40% of research-grade peptides tested from online suppliers showed purity discrepancies of 5% or more compared to stated specifications. And MOTS-C, a mitochondrial-derived peptide with a precise 16-amino-acid sequence, is particularly vulnerable to degradation during synthesis and storage. Even minor impurities. Residual solvents, truncated sequences, or oxidised methionine residues. Can render the compound inactive or introduce confounding variables into metabolic studies.

Our team at Real Peptides works directly with researchers who've learned this the hard way. The difference between publishable data and wasted months comes down to one thing most suppliers gloss over: independent verification of peptide purity before the vial ever reaches your lab.

How do you verify MOTS-C purity before using it in research?

To verify MOTS-C purity, request a Certificate of Analysis (COA) from the supplier showing HPLC purity ≥98%, mass spectrometry confirming the exact molecular weight (1,682.01 Da), and amino acid sequencing matching the 16-residue mitochondrial sequence. Third-party testing by accredited labs eliminates supplier bias. Genuine research-grade MOTS-C should include batch-specific data, not generic COAs reused across multiple shipments.

Here's what most guides miss: verifying MOTS-C purity isn't a one-time checkbox at purchase. Peptides degrade during storage. Even at −20°C. And reconstitution in improper solvents accelerates that process. This article covers the three lab tests that matter most, the red flags in supplier COAs that signal unreliable data, and the storage protocols that preserve purity between verification and use.

Why MOTS-C Purity Matters More Than Most Peptides

MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded directly in mitochondrial DNA, not nuclear DNA. Which makes its sequence uniqueness critical to its function. It regulates glucose metabolism by activating AMPK (AMP-activated protein kinase) in skeletal muscle and adipose tissue, shifting cells from glucose storage to fat oxidation. Even one amino acid substitution or truncation disrupts receptor binding at the MOTS-C-specific recognition site, rendering the peptide biologically inert.

The synthesis process for MOTS-C uses solid-phase peptide synthesis (SPPS), where amino acids are added sequentially to a growing chain. Each coupling step has a typical efficiency of 98–99%, meaning a 16-residue peptide synthesised with perfect efficiency would theoretically yield 75% of full-length product. And real-world synthesis rarely achieves perfect efficiency. The remaining 25% consists of deletion sequences (peptides missing one or more amino acids), incomplete cleavage from the resin, and residual protecting groups used during synthesis.

Purity below 95% means the vial contains a meaningful proportion of these synthesis byproducts, which can interfere with assays, bind non-specifically to cellular receptors, or trigger immune responses in animal models. When our team reviews failed MOTS-C studies, impurity is the single most common uncontrolled variable. Researchers assumed 'research-grade' meant verified, when in reality it just meant 'not pharmaceutical-grade.'

The Three Lab Tests That Verify MOTS-C Purity

Every legitimate MOTS-C supplier should provide documentation of three independent analytical methods: HPLC for purity percentage, mass spectrometry for molecular weight confirmation, and amino acid analysis for sequence verification. These aren't redundant. Each test catches different failure modes in the synthesis process.

HPLC (High-Performance Liquid Chromatography) separates peptide fragments by hydrophobicity. The resulting chromatogram shows peaks representing different molecular species in the sample. A pure MOTS-C sample produces one dominant peak representing the full-length peptide, with the area under that peak expressed as a percentage of total area. This is your purity figure. HPLC purity ≥98% is the standard for research-grade peptides. Anything below 95% contains too many deletion sequences or impurities to reliably attribute observed effects to MOTS-C itself.

Mass Spectrometry (MS) measures the mass-to-charge ratio of molecules in the sample. MOTS-C has a known molecular weight of 1,682.01 Da. Mass spec confirms the dominant species in your vial matches this exactly. A peak at 1,682.01 ± 0.5 Da confirms identity; peaks at lower masses indicate truncated sequences; peaks at higher masses suggest incomplete deprotection or aggregation. MS doesn't measure purity percentage. It confirms you have the right molecule.

Amino Acid Analysis (AAA) hydrolyzes the peptide and quantifies individual amino acids, then compares the ratio to the expected sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. If your sample shows excess glycine or proline relative to the expected 1:1:1 ratio across all residues, it indicates contamination with other peptides or incomplete synthesis. AAA is the slowest and most expensive test, which is why budget suppliers skip it. But it's the only method that catches sequence errors HPLC and MS might miss.

How to Read a MOTS-C Certificate of Analysis

A Certificate of Analysis (COA) is only as reliable as the lab that generated it. Supplier-generated COAs are not third-party verification. They're unaudited claims. Genuine third-party COAs list the testing lab's name, address, accreditation status (ISO 17025 is the standard), and the date of analysis. Batch numbers on the COA should match the batch number on your vial label exactly. If the supplier provides a single generic COA for all shipments, you have no verification that your specific batch was tested.

Look for these specific data points in every MOTS-C COA: HPLC purity expressed as a percentage (≥98% required), retention time in minutes (confirms the peptide eluted at the expected hydrophobicity), mass spec molecular weight (1,682.01 Da), and peptide content by weight (mg of actual peptide per mg of lyophilised powder). Peptide content accounts for residual water, salts, and counterions in the lyophilised product. A vial labeled '5mg MOTS-C' with 85% peptide content contains only 4.25mg of active compound.

Red flags that indicate unreliable data: no batch number, no testing lab listed, purity listed as '>95%' without an exact figure, mass spec data missing entirely, or a COA dated more than 12 months before your purchase. Peptides degrade over time even when stored correctly. A two-year-old COA tells you nothing about the current purity of the product you're holding. Real Peptides provides batch-specific, third-party COAs with every shipment because purity verification isn't optional. It's the foundation of reproducible research.

Verify MOTS-C Purity: Storage & Reconstitution Protocols

Even peptides shipped at 98% purity degrade if stored improperly. Lyophilised MOTS-C should be stored at −20°C in a desiccated environment. Exposure to moisture initiates hydrolysis of peptide bonds, particularly at the N-terminus. Once reconstituted, MOTS-C is stable for 2–4 weeks at 2–8°C when dissolved in sterile water or phosphate-buffered saline (PBS) at pH 7.4. Acidic or strongly basic solvents accelerate degradation.

The most common storage error we see: researchers reconstitute the entire vial at once, then freeze-thaw aliquots repeatedly for individual experiments. Every freeze-thaw cycle degrades peptide structure. Ice crystal formation physically shears peptide chains, and the temperature swing accelerates oxidation of methionine residues (MOTS-C contains two). Best practice: reconstitute only the volume needed for immediate use, and store the remaining lyophilised powder at −20°C. If you must prepare stock solutions, aliquot into single-use volumes and freeze once.

Reconstitution technique also affects purity. Add solvent slowly down the side of the vial. Never inject directly onto the lyophilised cake, which creates localized high concentrations that promote aggregation. Swirl gently to dissolve; do not vortex. Vigorous agitation introduces air bubbles that denature peptides at the air-liquid interface. After reconstitution, visually inspect the solution. It should be clear and colorless. Cloudiness, precipitate, or discoloration indicates aggregation or contamination, meaning the peptide is no longer usable regardless of the original purity specification.

MOTS-C Purity: Research-Grade vs Pharmaceutical-Grade Standards

Specification	Research-Grade (≥98%)	Pharmaceutical-Grade (≥99%)	Why It Matters for MOTS-C
HPLC Purity	98.0–99.5%	≥99.0%	MOTS-C at 98% contains ~2% deletion sequences that compete for receptor binding without activating AMPK
Endotoxin Level	<10 EU/mg	<1 EU/mg	In vivo studies require low endotoxin to avoid confounding inflammatory responses
Sterility Testing	Not required	USP sterility test required	Critical for any protocol involving injection or cell culture
Heavy Metals	Not specified	<10 ppm lead, <5 ppm arsenic	Trace metal contamination affects mitochondrial assays directly
Peptide Content	75–90% by weight	≥95% by weight	A '5mg' vial at 75% content delivers only 3.75mg MOTS-C
Bottom Line	Sufficient for cell culture and mechanistic studies; unsuitable for human or animal models without additional verification	Required for any clinical or regulatory submission; cost premium justified only when data must meet FDA or EMA standards

What If: MOTS-C Purity Scenarios

What If the COA Shows 96% Purity Instead of 98%?

Use it for preliminary screening or dose-response studies where minor impurities won't invalidate conclusions, but not for mechanistic work where you need to attribute effects solely to MOTS-C. The 4% impurity fraction likely contains (n-1) deletion sequences. Peptides missing one amino acid. Which may still bind the MOTS-C receptor but with altered affinity. If your study measures IC50, binding kinetics, or receptor specificity, that 4% contamination skews your data.

What If the Supplier Won't Provide a Batch-Specific COA?

Refuse the order. A supplier unwilling to provide batch-specific documentation either didn't test your batch or is hiding failed results. Generic COAs are a regulatory red flag. They indicate the supplier is selling untested product labeled with data from a different batch. In our experience, suppliers who resist providing batch-specific COAs are the same ones selling peptides that fail independent verification 60–70% of the time.

What If I Stored Reconstituted MOTS-C at Room Temperature Overnight?

Discard it. Even 12 hours at 20–25°C accelerates hydrolysis and oxidation beyond acceptable thresholds. You can't visually detect a 10% purity drop. The solution will still appear clear. But the degradation products interfere with assays and produce irreproducible results. The cost of replacing one vial is trivial compared to the cost of running an entire experiment on degraded peptide.

The Unfiltered Truth About MOTS-C Supplier Claims

Here's the honest answer: most online peptide suppliers don't synthesize MOTS-C themselves. They're resellers purchasing bulk powder from contract manufacturers in Asia, then repackaging it without independent verification. The 'research-grade' label is marketing, not a regulatory standard. We've seen suppliers list peptides as '>98% pure' when the actual tested purity was 89%, and others provide COAs showing purity measurements taken 18 months before the product shipped.

The business model works because most researchers don't verify purity independently. They trust the label, run their experiments, and blame their protocol when results don't replicate. Third-party testing costs $200–400 per sample, which makes it financially prohibitive to verify every vial. That's why supplier reputation matters more than price. A peptide that costs 30% less but arrives at 92% purity isn't a bargain. It's unusable.

Supplier transparency is the clearest signal of quality. If a company lists the synthesis method (SPPS), the testing lab (by name and location), and the specific batch number on every product page, they're confident in their supply chain. If they use vague language like 'laboratory tested' or 'highest purity available' without documentation, they're hiding something. Our standard at Real Peptides is simple: every shipment includes a batch-specific, third-party COA because your research deserves peptides you can trust without second-guessing the baseline purity.

Understanding how to verify MOTS-C purity transforms how you evaluate suppliers. The companies that provide transparent, batch-specific COAs and maintain cold-chain shipping aren't charging a premium for convenience. They're charging for accountability. If a supplier won't document purity to the same standard you'd expect from a reagent-grade chemical, their peptides don't belong in your research.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

HPLC purity ≥98% means that 98% or more of the peptide content in the vial is full-length, correctly sequenced MOTS-C, with the remaining 2% consisting of deletion sequences, residual solvents, or synthesis byproducts. HPLC separates molecules by hydrophobicity and measures the area under the peak corresponding to MOTS-C relative to total peak area. Purity below 95% introduces too many impurities to reliably attribute observed biological effects to MOTS-C alone.

No, verifying MOTS-C purity requires analytical instrumentation — specifically HPLC, mass spectrometry, or amino acid analysis — which are not available outside professional laboratories. Visual inspection can detect gross contamination (cloudiness, discoloration, precipitate) but cannot measure purity percentage or detect molecular-level impurities like deletion sequences or oxidized residues. The only reliable method for individual researchers is to request third-party COAs from accredited labs before purchase.

Third-party HPLC testing typically costs $150–250 per sample, mass spectrometry adds $100–150, and full amino acid analysis runs $200–400. Most researchers cannot afford to test every vial independently, which is why purchasing from suppliers who provide batch-specific, third-party COAs with every order is essential. Testing costs are justified only when verifying a new supplier or investigating unexpected research results.

MOTS-C below 95% purity contains deletion sequences that bind competitively to the same receptors without activating AMPK, effectively reducing the functional dose while introducing off-target effects. These impurities skew dose-response curves, reduce reproducibility across experiments, and can trigger immune responses in animal models. In metabolic studies, even 5% contamination alters glucose uptake assays and mitochondrial respiration measurements enough to invalidate conclusions about MOTS-C’s mechanism of action.

Yes, lyophilized MOTS-C undergoes slow degradation even at −20°C, primarily through oxidation of methionine residues and hydrolysis of peptide bonds in the presence of residual moisture. Peptides stored for 24 months at −20°C typically retain >95% of original purity, but after 36 months, purity often drops below 90%. Suppliers should include the synthesis date or expiration date on COAs — peptides older than 24 months from synthesis should be re-tested before use.

A legitimate third-party COA lists the testing laboratory’s full name, physical address, ISO 17025 accreditation number, and contact information. Search the lab name online to verify it exists as an independent entity, not a subsidiary of the peptide supplier. The COA should include the signature of a lab technician or quality manager, a unique report number, and a date of analysis within 6–12 months of your purchase. Generic COAs without lab identification or batch-specific details are not third-party verification.

Peptide content by weight measures the percentage of actual MOTS-C peptide in the lyophilized powder, accounting for residual moisture, salts (acetate or trifluoroacetate counterions), and other non-peptide material. A vial labeled ‘5mg MOTS-C’ with 80% peptide content contains only 4mg of active compound. This discrepancy affects dosing accuracy in biological assays — if you assume 5mg but deliver 4mg, your effective concentration is 20% lower than intended, which compounds across replicates and makes inter-study comparisons unreliable.

HPLC measures purity percentage and MS confirms molecular weight, but neither detects amino acid substitutions or sequence errors if the substituted amino acid happens to have the same mass as the correct one. Amino acid analysis hydrolyzes the peptide and quantifies individual amino acids, verifying the 1:1:1 ratio matches the expected sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. AAA is the only method that catches synthesis errors where the wrong amino acid was incorporated but the molecular weight remained unchanged.

It depends on your experimental design. For preliminary screening or high-dose treatments where the 8% impurity is unlikely to confound results, 92% purity may be acceptable. For mechanistic studies, receptor binding assays, or dose-response curves where precision matters, 92% purity introduces too much variability — the deletion sequences and byproducts will compete for binding and skew your IC50 or EC50 measurements. If the data will inform further studies or be published, use ≥98% purity to eliminate purity as a confounding variable.

Each freeze-thaw cycle degrades peptide structure through two mechanisms: ice crystal formation physically shears peptide chains, and the temperature swing accelerates oxidation of methionine residues at positions 1 and 6 in the MOTS-C sequence. Purity drops approximately 2–5% per cycle depending on storage conditions. After three freeze-thaw cycles, a peptide initially at 98% purity may measure 88–92%, with the degraded fraction consisting of oxidized and aggregated species that interfere with assays. Aliquot reconstituted solutions into single-use volumes to avoid repeated freezing.

No. Research-grade peptides are synthesized and tested for laboratory use only — they are not manufactured under Good Manufacturing Practice (GMP) standards, do not undergo sterility or endotoxin testing required for human administration, and are not approved by the FDA or any regulatory body for clinical use. Using research-grade MOTS-C in humans carries significant risk of contamination, incorrect dosing, and adverse reactions. Only pharmaceutical-grade peptides produced under GMP and prescribed by licensed physicians are appropriate for human use.

Listing purity as ‘>95%’ without an exact percentage is a red flag indicating the supplier either did not perform quantitative HPLC testing or is obscuring a result below their claimed standard. Legitimate HPLC analysis produces a precise purity percentage (e.g., 98.3%) derived from integrating peak areas in the chromatogram. Vague purity claims like ‘>95%’ or ‘high purity’ suggest the supplier is reselling untested peptide or providing data from a different batch. Always request the exact HPLC purity percentage and corresponding chromatogram before purchasing.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA